Trial ID or NCT#

NCT02316548

Status

RECRUITING

Purpose

This randomized phase II trial studies the side effects and how well postoperative intensity modulated radiotherapy works after surgery in treating patients with urothelial bladder cancer. Radiation therapy uses high energy x-rays to kill tumor cells left behind in the pelvis after surgery. It is not yet known whether surgery followed by radiotherapy is more effective than surgery alone in treating patients with urothelial bladder cancer.

Official Title

Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Mark K Buyyounouski, MD, MS
Genitourinary specialist, Radiation oncologist
Associate Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Mark K. Buyyounouski
(650) 498-7061